<?xml version="1.0" encoding="UTF-8"?>
<p>Further assessment is necessary before confirming the effectiveness of such combination therapy. In addition, to prevent further community and nosocomial spread of COVID-19, the postprocedure risk management program should not be neglected (
 <xref rid="B309" ref-type="bibr">309</xref>). Development of broad-spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (
 <xref rid="B203" ref-type="bibr">203</xref>). A promising animal study revealed the protective effect of passive immunotherapy with immune serum from MERS-immune camels on mice infected with MERS-CoV (
 <xref rid="B204" ref-type="bibr">204</xref>). Passive immunotherapy using convalescent plasma is another strategy that can be used for treating COVID-19-infected, critically ill patients (
 <xref rid="B205" ref-type="bibr">205</xref>).
</p>
